Clinical efficacy study of neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for resectable pancreatic cancer

Clinical efficacy study of neoadjuvant therapy with intensity-modulated radiotherapy combined with S-1 for resectable pancreatic cancer - NAC-IMRT for resectable pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046456

Enrollment

Registered

2021-12-25

Start date

2020-10-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

intensity-modulated radiotherapy combined with S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients with resectable pancreatic 2.Pathological diagnosis 3.Biliary drainage for obstructive jaundice 4.Given consent for this clinical trial

Exclusion criteria

Exclusion criteria: 1.Performance status: 2-4 (according to ECOG criteria) 2.Difficulty in oral intake 3.Severe hepatic or renal impairment 4.Active infectious disease 5.History of radiation therapy for abdominal organs 6.In case the attending physician deems it inappropriate

Design outcomes

Primary

Measure	Time frame
progression free survival for 2 years	—

Countries

Japan

Contacts

Public ContactYusuke Okamura

Kyoto Katsura Hospital Surgery

yusuke531979@yahoo.co.jp075-391-5811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026